Cargando…

Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients

Dysregulated fluid homeostasis is frequent in haemodialysis (HD) patients and is linked to inflammation which may be elicited by endotoxemia. The impact of hypervolemia on immune cells has not been studied in detail. Therefore, we analysed the hypervolemic activation of peripheral blood mononuclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulrich, Christof, Wilke, Annegret, Schleicher, Nadja, Girndt, Matthias, Fiedler, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150829/
https://www.ncbi.nlm.nih.gov/pubmed/32138278
http://dx.doi.org/10.3390/toxins12030159
_version_ 1783521108107984896
author Ulrich, Christof
Wilke, Annegret
Schleicher, Nadja
Girndt, Matthias
Fiedler, Roman
author_facet Ulrich, Christof
Wilke, Annegret
Schleicher, Nadja
Girndt, Matthias
Fiedler, Roman
author_sort Ulrich, Christof
collection PubMed
description Dysregulated fluid homeostasis is frequent in haemodialysis (HD) patients and is linked to inflammation which may be elicited by endotoxemia. The impact of hypervolemia on immune cells has not been studied in detail. Therefore, we analysed the hypervolemic activation of peripheral blood mononuclear cells (PBMCs) in HD with special focus on the NLRP3 inflammasome response. First, 45 HD were included in the observational study. Immune parameters including cell counts, caspase-1, oxidative stress, cytokine gene expression and serum analysis (IL-1ß, IL-6, IL-10) were all measured at two time points. Fluid status was evaluated by electrical bioimpedance vector analysis, defining hypervolemia (H) as >75 vector percentile. Then, 17 patients were classified as hypervolemic (H-HD), 19 as normovolemic (N-HD) and 9 failed to meet the inclusion criteria. Monocytes were elevated and lymphocytes were decreased by hypervolemia. NLRP3 inflammasome components, caspase-1 and IL-1ß expression were not statistically different between the two groups. Serum IL-6 levels were significantly elevated in H-HD. IL-10 mRNA transcripts were elevated by 2-fold in H-HD but were not efficiently translated. We conclude that the NLRP3 inflammasome is not activated by hypervolemia thus refuting the thesis that endotoxemia may be a main driver for inflammation in H-HD. Nevertheless, inflammation is generally higher in H-HD compared to N-HD patients and is not sufficiently balanced by anti-inflammatory mechanisms.
format Online
Article
Text
id pubmed-7150829
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71508292020-04-20 Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients Ulrich, Christof Wilke, Annegret Schleicher, Nadja Girndt, Matthias Fiedler, Roman Toxins (Basel) Article Dysregulated fluid homeostasis is frequent in haemodialysis (HD) patients and is linked to inflammation which may be elicited by endotoxemia. The impact of hypervolemia on immune cells has not been studied in detail. Therefore, we analysed the hypervolemic activation of peripheral blood mononuclear cells (PBMCs) in HD with special focus on the NLRP3 inflammasome response. First, 45 HD were included in the observational study. Immune parameters including cell counts, caspase-1, oxidative stress, cytokine gene expression and serum analysis (IL-1ß, IL-6, IL-10) were all measured at two time points. Fluid status was evaluated by electrical bioimpedance vector analysis, defining hypervolemia (H) as >75 vector percentile. Then, 17 patients were classified as hypervolemic (H-HD), 19 as normovolemic (N-HD) and 9 failed to meet the inclusion criteria. Monocytes were elevated and lymphocytes were decreased by hypervolemia. NLRP3 inflammasome components, caspase-1 and IL-1ß expression were not statistically different between the two groups. Serum IL-6 levels were significantly elevated in H-HD. IL-10 mRNA transcripts were elevated by 2-fold in H-HD but were not efficiently translated. We conclude that the NLRP3 inflammasome is not activated by hypervolemia thus refuting the thesis that endotoxemia may be a main driver for inflammation in H-HD. Nevertheless, inflammation is generally higher in H-HD compared to N-HD patients and is not sufficiently balanced by anti-inflammatory mechanisms. MDPI 2020-03-03 /pmc/articles/PMC7150829/ /pubmed/32138278 http://dx.doi.org/10.3390/toxins12030159 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ulrich, Christof
Wilke, Annegret
Schleicher, Nadja
Girndt, Matthias
Fiedler, Roman
Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients
title Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients
title_full Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients
title_fullStr Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients
title_full_unstemmed Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients
title_short Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients
title_sort hypervolemia-induced immune disturbances do not involve il-1ß but il-6 and il-10 activation in haemodialysis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150829/
https://www.ncbi.nlm.nih.gov/pubmed/32138278
http://dx.doi.org/10.3390/toxins12030159
work_keys_str_mv AT ulrichchristof hypervolemiainducedimmunedisturbancesdonotinvolveil1ßbutil6andil10activationinhaemodialysispatients
AT wilkeannegret hypervolemiainducedimmunedisturbancesdonotinvolveil1ßbutil6andil10activationinhaemodialysispatients
AT schleichernadja hypervolemiainducedimmunedisturbancesdonotinvolveil1ßbutil6andil10activationinhaemodialysispatients
AT girndtmatthias hypervolemiainducedimmunedisturbancesdonotinvolveil1ßbutil6andil10activationinhaemodialysispatients
AT fiedlerroman hypervolemiainducedimmunedisturbancesdonotinvolveil1ßbutil6andil10activationinhaemodialysispatients